A Study of ALN-HBV in Healthy Adult Volunteers and Non-cirrhotic Patients With Chronic Hepatitis B Virus (HBV) Infection
A Phase 1/2, Randomized, Single-Blind, Placebo-Controlled, Single-Ascending and Multiple-Ascending Dose, Safety, Tolerability, Pharmacokinetics, and Antiviral Efficacy Study of Subcutaneously Administered ALN-HBV in Healthy Adult Subjects and Non-cirrhotic Patients With Chronic Hepatitis B Virus (HBV) Infection
Sponsor: Alnylam Pharmaceuticals
Terminated
This trial was terminated. No reason was provided.
This PHASE1 trial investigates Chronic Hepatitis B and HBV and is currently terminated or withdrawn. Alnylam Pharmaceuticals leads this study, which shows 10 recorded versions since 2016 — indicating substantial longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE1
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE1
-
Oct 2018 — Jan 2021 [monthly]
Terminated PHASE1
Phase: PHASE1_PHASE2 → PHASE1
▶ Show 5 earlier versions
-
Jun 2018 — Oct 2018 [monthly]
Terminated PHASE1_PHASE2
-
Dec 2017 — Jun 2018 [monthly]
Terminated PHASE1_PHASE2
Status: Active Not Recruiting → Terminated
-
Sep 2017 — Dec 2017 [monthly]
Active Not Recruiting PHASE1_PHASE2
Status: Recruiting → Active Not Recruiting
-
Jul 2017 — Sep 2017 [monthly]
Recruiting PHASE1_PHASE2
-
Jan 2017 — Jul 2017 [monthly]
Recruiting PHASE1_PHASE2
First recorded
Jun 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Alnylam Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .